GlaxoSmithKline (GSK) has partnered with Xiamen Innovax Biotech to support the development of a recombinant protein-based vaccine candidate against Covid-19.
The vaccine candidate, Covid-19 XWG-03, is being developed by Innovax Biotech in alliance with Xiamen University, based on multiple truncated S (spike) proteins.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAs part of the collaboration, GSK agreed to offer its pandemic adjuvant system for preclinical assessment of the vaccine candidate.
During the preclinical testing, Innovax Biotech will evaluate the series of S proteins related to the vaccine candidate to establish a lead candidate based on immunogenicity data.
Initially, GSK partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to provide access to its pandemic vaccine adjuvant platform to help support Covid-19 vaccine candidates.
An adjuvant is intended decrease the amount of antigen per dose and enable the manufacture of more vaccine doses.
The CEPI agreed to manage any arrangements between companies or researchers who want to test their vaccine platform with GSK’s adjuvant technology to create coronavirus vaccines.
The first deal for GSK’s technology was signed by the University of Queensland in Australia, followed by Clover Biopharmaceuticals.
Over the past month, GSK forged alliances with multiple companies and research groups globally, including in the US and China.
According to early data from preclinical studies by one of the partners, the adjuvant demonstrated encouraging profile.
In a statement, GSK said: “Early indications of the adjuvant’s benefit have been reported in the first pre-clinical experiments by one of the collaborations.
“GSK expects data to be reported from the various collaborations over the next three months and these data will inform next steps for clinical development of the candidate vaccines.”
The company is exploring additional partnership opportunities, along with approaches to help scale manufacturing and production for a vaccine in the future.
